127 related articles for article (PubMed ID: 20407410)
1. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972.
Reyes MP; Palutke WA; Wylin RF
Medicine (Baltimore); 1973 May; 52(3):173-94. PubMed ID: 20407410
[No Abstract] [Full Text] [Related]
2. [Active drugs against Pseudomonas aeruginosa and their clinical usefulness].
Gobernado M
Rev Clin Esp; 1998 Sep; 198 Suppl 2():51-61. PubMed ID: 9844479
[No Abstract] [Full Text] [Related]
3. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.
Mahar P; Padiglione AA; Cleland H; Paul E; Hinrichs M; Wasiak J
Burns; 2010 Dec; 36(8):1228-33. PubMed ID: 20965109
[TBL] [Abstract][Full Text] [Related]
4. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin.
Gavin PJ; Suseno MT; Cook FV; Peterson LR; Thomson RB
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):427-30. PubMed ID: 14522517
[TBL] [Abstract][Full Text] [Related]
5. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Edgeworth JD; Merante D; Patel S; Young C; Jones P; Vithlani S; Wyncoll D; Roberts P; Jones A; Den Nagata T; Ariyasu M; Livermore DM; Beale R
Clin Infect Dis; 2019 May; 68(11):1932-1934. PubMed ID: 30418554
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa endocarditis in renal transplant recipients.
Nasim A; Baqi S; Akhtar SF
Transpl Infect Dis; 2012 Apr; 14(2):180-3. PubMed ID: 21883760
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas endocarditis.
Saroff AL; Armstrong D; Johnson WD
Am J Cardiol; 1973 Aug; 32(2):234-7. PubMed ID: 4352782
[No Abstract] [Full Text] [Related]
9. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.
Reyes MP; Lerner AM
Rev Infect Dis; 1983; 5(2):314-21. PubMed ID: 6405476
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas mendocina, an environmental bacterium isolated from a patient with human infective endocarditis.
Aragone MR; Maurizi DM; Clara LO; Navarro Estrada JL; Ascione A
J Clin Microbiol; 1992 Jun; 30(6):1583-4. PubMed ID: 1624580
[TBL] [Abstract][Full Text] [Related]
11. Prosthetic valve endocarditis caused by Pseudomonas luteola.
Casalta JP; Fournier PE; Habib G; Riberi A; Raoult D
BMC Infect Dis; 2005 Oct; 5():82. PubMed ID: 16221303
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Pseudomonas aeruginosa infective endocarditis via haemodialysis outpatient parenteral antimicrobial therapy: case report.
Maxwell-Scott H; Thangarajah R; Arnold A; Wade P; Klein JL
J Antimicrob Chemother; 2019 Jun; 74(6):1757-1759. PubMed ID: 30830217
[No Abstract] [Full Text] [Related]
14. In Vitro Antibiotic Susceptibility of Pseudomonas aeruginosa Corneal Ulcer Isolates.
Gupta S; Mittal S; Nayak N; Satpathy G; Khokhar S; Agarwal T
Ocul Immunol Inflamm; 2015 Jun; 23(3):252-5. PubMed ID: 24564536
[No Abstract] [Full Text] [Related]
15. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis.
Juan C
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Dec; 37(10):623-625. PubMed ID: 31611061
[No Abstract] [Full Text] [Related]
17. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
[TBL] [Abstract][Full Text] [Related]
18. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
[No Abstract] [Full Text] [Related]
19. [Bacteremia, endocarditis and meningitis caused by Pseudomonas aeruginosa].
Cisneros Herreros JM; Cañas García-Otero E; Caballero Granado J; Becerril Carral B
Rev Clin Esp; 1998 Sep; 198 Suppl 2():25-9. PubMed ID: 9844475
[No Abstract] [Full Text] [Related]
20. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
